Breaking News
November 16, 2018 - ACC Latin America Conference brings experts to discuss latest cardiovascular science
November 16, 2018 - Pooled analysis of Intersect ENT’s steroid releasing implants in patients after frontal sinus surgery to be published
November 16, 2018 - Expectations about pain intensity can become self-fulfilling prophecies
November 16, 2018 - NIH awards $3.4 million to UC researchers to study gastrointestinal lymphatic system
November 16, 2018 - Scientist Dr David Taylor of MR Solutions is a finalist in the BMW i UK Tech Founder Awards
November 16, 2018 - Earlier treatment could help reverse autistic-like behavior in tuberous sclerosis
November 16, 2018 - Vegetables and salad may include bacteria that are resistant to antibiotics
November 16, 2018 - Endocrine Society chooses four Diabetes Caucus leaders as winners of Diabetes Champion Award
November 16, 2018 - Brain and muscle cells found within kidney organoids
November 16, 2018 - Person’s sex hormones may play key role in trauma survival, finds study
November 16, 2018 - PTEN Genetic Test: MedlinePlus Lab Test Information
November 16, 2018 - Toxic metal pollution linked with development of autism spectrum disorder
November 16, 2018 - Calcified nodules in the retina increase risk for progression to late stages of AMD
November 16, 2018 - ZEISS teams up with arivis AG to offer complete 3D imaging solutions
November 16, 2018 - Georgia State professor receives $1.2 million grant to study how the brain controls eating behavior
November 16, 2018 - Specific bacterial toxins reduce number of cells suppressing immune response
November 16, 2018 - Review by ID physician improves outcomes for outpatient parenteral antimicrobial therapy
November 16, 2018 - Conditions that produce signs similar to arthritis
November 16, 2018 - AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
November 16, 2018 - Surgery remains best treatment for appendicitis, Stanford study finds
November 16, 2018 - Non-surgical fistula creation system Ellipsys becomes key focus of attention at CiDA
November 16, 2018 - Researchers find no link between ‘allergy friendly’ dogs and lower risk of asthma
November 16, 2018 - Researchers elucidate new rules of connectivity of neurons in the neocortex
November 16, 2018 - Treating children with ‘bubble baby disease’
November 16, 2018 - Nexus announces availability of Arsenic Trioxide Injection in the US
November 16, 2018 - Researchers find metabolite shuttle between cells in the liver that may combat tissue fibrosis
November 16, 2018 - AHA: PTSD Common Among Those Who Suffer Tear in the Aorta’s Wall
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
November 16, 2018 - Inexpensive, portable air purifier could help protect the heart from pollution
November 16, 2018 - New 15-minute scan could help diagnose brain damage in babies up to two years old
November 16, 2018 - Deep brain stimulation not effective for treating early Alzheimer’s
November 16, 2018 - Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
November 16, 2018 - What This Pond Protist Does With Its Genome Will Astound You
November 15, 2018 - Researchers develop tool that speeds up analysis and publication of biomedical data
November 15, 2018 - Scientists identify mechanism used by lung cancer cells to obtain glucose
November 15, 2018 - Abnormalities in development of the brain could be involved in onset of autism, finds new study
November 15, 2018 - Soy protein equally effective as animal protein in building muscle strength
November 15, 2018 - American Academy of Pediatrics, Nov. 2-6
November 15, 2018 - Dopamine drives early addiction to heroin
November 15, 2018 - Variance in gut microbiome in Himalayan populations linked to dietary lifestyle | News Center
November 15, 2018 - Reducing Cardiovascular Disease: The Amish Way
November 15, 2018 - King’s researchers launch charter to guide organizations to engage abuse survivors in research
November 15, 2018 - Enable Injections enters into development agreements with UCB and Apellis Pharmaceuticals
November 15, 2018 - TGen North collaborates with NARBHA Institute to advance human health
November 15, 2018 - Researchers discover molecular basis for therapeutic actions of an African folk medicine
November 15, 2018 - Human Cell Atlas study of early pregnancy shows how mother’s immune system is modified
November 15, 2018 - New guidelines for detecting and managing sarcopenia to be launched in the UK
November 15, 2018 - Researchers explore role of dietary composition on energy expenditure
November 15, 2018 - Elsevier launches Entellect™ Platform, unlocking value by creating AI-ready life sciences data
November 15, 2018 - Now that cannabis is legal in Canada, let’s use it to tackle the opioid crisis
November 15, 2018 - In the Spotlight: At the intersection of tech, health, and ethics
November 15, 2018 - Traditional Glaucoma Test Can Miss Severity of the Disease
November 15, 2018 - Researchers directly connect activities of genes with instinctive behavior in male cichlids
November 15, 2018 - Salk researchers report new methods to identify AD drug candidates with anti-aging properties
November 15, 2018 - St. Jude Hospital announces availability of largest collections of leukemia samples
November 15, 2018 - Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
November 15, 2018 - Designing a novel cell-permeable peptide chimera to promote wound healing
November 15, 2018 - NEI investigators combine two imaging modalities to view the retina in unprecedented detail
November 15, 2018 - Determining how hearts develop to better understand congenital heart defects
November 15, 2018 - Maverick immune cells can act independently to identify and kill cancer cells, finds research
November 15, 2018 - Advanced AI and big data methods to tackle dementia
November 15, 2018 - Report reveals increase in pancreatic cancer death rates across Europe
November 15, 2018 - Luxia Scientific announces availability of its gut microbiome test in Luxembourg
November 15, 2018 - New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis
November 15, 2018 - New approach targets matrix surrounding neurons to protect neurons after stroke
November 15, 2018 - Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine
November 15, 2018 - Heart failure patients shouldn’t stop meds even if condition improves: study
November 15, 2018 - Parents and carers of people with diabetes experience emotional or mental health problems
New synthetic compound based on brain hormone holds promise for cancer treatment

New synthetic compound based on brain hormone holds promise for cancer treatment

image_pdfDownload PDFimage_print

A lab team led by Nobel Prize winner Dr. Andrew Schally at the Miami Veterans Affairs Healthcare System and the University of Miami showed that a synthetic compound based on a brain hormone spurred the growth of cancer cells in Petri dishes but enigmatically had the opposite effect in mice.

The surprising discovery, reported online in the Proceedings of the National Academy of Sciences (PNAS) on Oct. 29, 2018, holds promise for cancer treatment. But it is also important because the manmade compound and others like it have shown beneficial effects in preclinical studies to treat a range of medical conditions affecting the heart, pancreas, eyes, and other organs. That’s because the compounds spur the growth of new healthy tissue. Tests in animal models suggest, for example, that they could help grow new heart muscle cells after a heart attack.

The compound tested in the new PNAS report, MR409, is one of several patented analogs, or derivatives, made in Schally’s lab based on growth hormone-releasing hormone, or GHRH. GHRH is made in the brain’s hypothalamus. It triggers the production and release of growth hormone in the pea-sized pituitary gland, located near the base of the brain. Growth hormone, in turn, is essential for human growth and cell regeneration.

The fear among Schally and his scientist peers, though, was that while GHRH analogs might be potent medicine for some conditions, they might at the same time cause cancer cells to grow, due to their growth-stimulating properties.

“I was concerned,” says Schally. “GHRH, in addition to being a brain hormone, is a powerful growth factor. I was afraid it would be stimulatory to tumors. Imagine us using it in patients with heart disease or diabetes and seeing cancers appear. That would make it completely unacceptable as a therapy.”

That’s precisely what MR409 did when applied to cell cultures in the latest experiments: It caused lung cancer cells from human tumors to multiply and spread, and kept them from dying.

But the hormone analog had the opposite effect when injected into mice with implanted human tumors: Not only did the compound not feed the cancer cells, it caused them to stop growing. It had this effect on lung, pancreatic, gastric, bladder, prostate, breast, and colorectal cancers. The analog, paradoxically, worked like counterpart analogs known as antagonists that are designed to block, not mimic, the action of GHRH.

“These are very welcome findings,” notes the VA Nobelist. “They may alleviate serious concerns about stimulating growth of cancers with GHRH agonists in the course of therapy for other diseases and conditions.”

Agonists are analogs that act like a key in a lock to initiate a biochemical reaction in the body. In the key-lock analogy, the lock is a receptor–a protein on the cell surface that interacts with the agonist to trigger a reaction. Antagonists, on the other hand, jam up the receptor so no reaction can occur. GHRH antagonists have been tested extensively by Schally’s group and others for their ability to inhibit tumors.

Schally and his team believe the most likely reason for MR409’s tumor-inhibitory effect in mice is the down-regulation of GHRH receptors in the pituitary gland and in the tumors themselves. That effect, which can occur only in live animals and not in isolated cells, may explain the dramatic difference between the analog’s effect in cells versus in the organism.

“The receptors transmit the hormonal message,” explains Schally. “When there are fewer receptors on the cell surface, this blocks the effect of endogenous [produced within the body] GHRH found in tumors, and thereby blocks tumor growth.”

He notes that the receptor-squashing effect is like that seen with luteinizing hormone-releasing hormone (LHRH), which, like GHRH, is produced in the brain’s hypothalamus. A treatment for aggressive prostate cancer that is based on LHRH agonists, stemming from Schally’s early discoveries, was introduced in 1984 and is used widely around the world.

Schally says the down-regulation of receptors that results from continuous treatment with analogs is like a lock being worn out to the point where it no longer works, and turning the key has no effect.

The journal article by Schally’s team is accompanied by a commentary by Drs. Hippokratis Klaris and Ioulia Chatzistamou at the University of South Carolina. They write that MR409 and similar GHRH agonists, given the “virtual absence of toxicity” seen in the newest experiments and past ones, should have “wide effectiveness in diverse cancers” and also hold promise for other diseases and conditions.

The latest findings represent the continuation of decades of VA-supported work from Schally’s team, much of it looking at how to stop cancer through hormone-based treatment. At age 91, the scientist still works daily in his research lab in VA, as he has done since 1962. His lab moved from the New Orleans VA to the Miami VA after Hurricane Katrina in 2005. He shared the Nobel Prize in Medicine or Physiology in 1977 for identifying the structure of hormonal peptides in the brain.

GHRH agonists must still be tested in clinical trials in the U.S. before they can be used in routine patient care. That can be a long road, taking several years. But Schally says he is optimistic, in light of his team’s latest results.

“I’m not a clinician, but now I have no reservation in recommending the agonists for various clinical uses.” In terms of cancer therapy, he notes the insights gained in the latest study will benefit the further development not only of MR409 and other GHRH agonists, but also GHRH antagonists. He envisions clinicians eventually being able to choose between GHRH agonists and antagonists for cancer treatment.

Source:

https://www.research.va.gov/currents/1118-Brain-derived-compounds-show-surprising-results-for-cancer.cfm

Tagged with:

About author

Related Articles